HC Wainwright & Co. analyst Sean Lee downgrades Kazia Therapeutics (NASDAQ:KZIA) from Buy to Neutral.
HC Wainwright & Co. Downgrades Kazia Therapeutics to Neutral
HC Wainwright & Co. analyst Sean Lee downgrades Kazia Therapeutics (NASDAQ:KZIA) from Buy to Neutral.
Related Posts
Morgan Stanley Maintains Equal-Weight on RenaissanceRe Holdings, Lowers Price Target to $150
Morgan Stanley analyst Michael Phillips maintains RenaissanceRe Holdings (NYSE:RNR) with a Equal-Weight and lowers the price target from $162 to $150.
Morgan Stanley Maintains Underweight on MGE Energy, Lowers Price Target to $75
Morgan Stanley analyst Stephen Byrd maintains MGE Energy (NASDAQ:MGEE) with a Underweight and lowers the price target from $77 to $75.
Stephens & Co. Maintains Equal-Weight Rating for Ryder System: Here’s What You Need To Know
Stephens & Co. has decided to maintain its Equal-Weight rating of Ryder System (NYSE:R) and lower its price…